These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 1801751)
1. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Schmitt M; Goretzki L; Jänicke F; Calvete J; Eulitz M; Kobayashi H; Chucholowski N; Graeff H Biomed Biochim Acta; 1991; 50(4-6):731-41. PubMed ID: 1801751 [TBL] [Abstract][Full Text] [Related]
2. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). Kobayashi H; Schmitt M; Goretzki L; Chucholowski N; Calvete J; Kramer M; Günzler WA; Jänicke F; Graeff H J Biol Chem; 1991 Mar; 266(8):5147-52. PubMed ID: 1900515 [TBL] [Abstract][Full Text] [Related]
3. Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin. Schmitt M; Kanayama N; Jänicke F; Hafter R; Graeff H Adv Exp Med Biol; 1991; 297():111-28. PubMed ID: 1837419 [TBL] [Abstract][Full Text] [Related]
4. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis]. Kobayashi H Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830 [TBL] [Abstract][Full Text] [Related]
5. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Schmitt M; Jänicke F; Graeff H Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250 [TBL] [Abstract][Full Text] [Related]
6. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. Goretzki L; Schmitt M; Mann K; Calvete J; Chucholowski N; Kramer M; Günzler WA; Jänicke F; Graeff H FEBS Lett; 1992 Feb; 297(1-2):112-8. PubMed ID: 1551416 [TBL] [Abstract][Full Text] [Related]
8. Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA). Schmitt M; Kanayama N; Henschen A; Hollrieder A; Hafter R; Gulba D; Jänicke F; Graeff H FEBS Lett; 1989 Sep; 255(1):83-8. PubMed ID: 2529137 [TBL] [Abstract][Full Text] [Related]
9. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis. Zhu F; Jia S; Xing G; Gao L; Zhang L; He F DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166 [TBL] [Abstract][Full Text] [Related]
10. [The clinical prospects for the study of the plasminogen activation system in breast cancer]. Gershteĭn ES; Kushlinskiĭ NE Vestn Ross Akad Med Nauk; 1999; (8):58-61. PubMed ID: 10487126 [TBL] [Abstract][Full Text] [Related]
11. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine). Petersen LC Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959 [TBL] [Abstract][Full Text] [Related]
12. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. Schmitt M; Wilhelm O; Jänicke F; Magdolen V; Reuning U; Ohi H; Moniwa N; Kobayashi H; Weidle U; Graeff H J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):151-65. PubMed ID: 8556577 [TBL] [Abstract][Full Text] [Related]
13. Inactivation of human tumor cell pro-urokinase by granulocyte elastase. Kanayama N; Terao T Jpn J Cancer Res; 1990 Oct; 81(10):994-1002. PubMed ID: 2121685 [TBL] [Abstract][Full Text] [Related]
14. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase. Vines DJ; Lee SW; Dichek DA; Ellis V J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879 [TBL] [Abstract][Full Text] [Related]
15. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. List K; Jensen ON; Bugge TH; Lund LR; Ploug M; Danø K; Behrendt N Biochemistry; 2000 Jan; 39(3):508-15. PubMed ID: 10642175 [TBL] [Abstract][Full Text] [Related]
16. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Tang L; Han X Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006 [TBL] [Abstract][Full Text] [Related]
17. Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. Kobayashi H; Ohi H; Shinohara H; Sugimura M; Fujii T; Terao T; Schmitt M; Goretzki L; Chucholowski N; Jänicke F Br J Cancer; 1993 Mar; 67(3):537-44. PubMed ID: 8382511 [TBL] [Abstract][Full Text] [Related]
18. A monoclonal antibody that recognizes the receptor binding region of human urokinase plasminogen activator. Nolli ML; Corti A; Soffientini A; Cassani G Thromb Haemost; 1986 Oct; 56(2):214-8. PubMed ID: 2433787 [TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599 [TBL] [Abstract][Full Text] [Related]
20. In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells. Luparello C; Del Rosso M Eur J Cancer; 1996 Apr; 32A(4):702-7. PubMed ID: 8695276 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]